Positioning no disclosures inside 60 days, left as found
Options put/call open interest 19.10, read 2026-11-02
Ethical does not pass the values gate
Price9.49 USD
Fair valueUnder review
Ethical score70.0/100
Our investment reviews on this name
2026-09-19Read Markdown14.40-34.1% to today ✓Markup gives way to Markdown after a 42% slide in 11 weeks
2026-07-02Read Markup24.89-61.9% to today First review on file: Markup
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
Aeva Technologies, Inc. holds its Markdown at $9.49. Elevated stress, defensive posture warranted, held for 39 days.
As held on the ledger · 2026-11-04
Phase
Markdown · caution
Quantitative state
Elevated stress, defensive posture warranted, held for 39 days
Price at the screen
$9.49
Valuation
N/A trailing · -8.96 forward price to earnings
Values screen
FAIL· score 70.0
Beta
2.43
The Workings
Five Screens, Shown in Full
Does not pass. Debt ratio
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
56.98%
Below 33%
Interest-bearing debt is 57.0% of its assets, above the one-third ceiling the screen allows.
Fail
Interest-bearing cash
27.61%
Below 33%
Cash held in interest-bearing accounts and securities is 27.6% of assets, under the one-third limit.
Pass
Receivables
42.10%
Below 49%
Money owed to the company is 42.1% of assets, under the 49% limit.
Pass
Revenue purity
15.14%
Below 5%
15.1% of revenue comes from non-compliant sources, over the 5% line.
Fail
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Falls Short, in Plain English
Aeva Technologies,'s business is in a permissible area, but its interest-bearing debt is about 57% of the company, well over the ~33% line, so it does not pass on the financial screens.
Read as at 2026-11-05. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when AEVA's ethical verdict changes
Today AEVA does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
What the Numbers Say It Is Worth
The Fair Value Range
Fair value under review. Our model's value is 2.85x the price, above our 2.00x limit. We show no fair value, margin of safety or value read built on it until the review clears.
Another profit measure, before interest, tax and non-cash costs: EBITDA.
The risks · The things to watch: it's a small-cap, so the share price can swing harder than the market; it already moves more than the market on an average day; it carries a real debt load, which raises the stakes if revenue slips.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
AEVA trades on Nasdaq. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-11-04Markdown$8.94-3.6%Entry 19
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 3.6% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it D. Technically it is momentum reading oversold. Over the past year the shares are up 2%. Our forward projection puts the odds of a 10% gain over the next month near 46%. The street (5 analysts) rates it none, with a mean price target of $24. It reported earnings in this window, a natural checkpoint for the thesis.
2026-11-03Markdown$9.27+0.0%Entry 18
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it D. Technically it is momentum reading oversold. Over the past year the shares are up 2%. Our forward projection puts the odds of a 10% gain over the next month near 46%. The street (5 analysts) rates it none, with a mean price target of $24. It reported earnings in this window, a natural checkpoint for the thesis.
2026-11-02Markdown$9.27+0.0%Entry 17
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it D. Technically it is momentum reading oversold. Over the past year the shares are up 2%. Our forward projection puts the odds of a 10% gain over the next month near 46%. The street (5 analysts) rates it none, with a mean price target of $24. It reported earnings in this window, a natural checkpoint for the thesis.
2026-11-01Markdown$9.27-11.2%Entry 16
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 11.2% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it D. Technically it is momentum reading oversold. Over the past year the shares are up 2%. Our forward projection puts the odds of a 10% gain over the next month near 46%. The street (5 analysts) rates it none, with a mean price target of $24. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-31Markdown$10.44+0.0%Entry 15
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it D. Technically it is momentum reading oversold. Over the past year the shares are up 2%. Our forward projection puts the odds of a 10% gain over the next month near 46%. The street (5 analysts) rates it none, with a mean price target of $24. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-30Markdown$10.44+0.0%Entry 14
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it D. Technically it is momentum reading oversold. Over the past year the shares are up 2%. Our forward projection puts the odds of a 10% gain over the next month near 46%. The street (5 analysts) rates it none, with a mean price target of $24. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-29Markdown$10.44-5.0%Entry 13
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 5.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it D. Technically it is momentum reading oversold. Over the past year the shares are up 2%. Our forward projection puts the odds of a 10% gain over the next month near 46%. The street (5 analysts) rates it none, with a mean price target of $24. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-28Markdown$10.99+0.0%Entry 12
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it D. Technically it is momentum reading oversold. Over the past year the shares are up 2%. Our forward projection puts the odds of a 10% gain over the next month near 46%. The street (5 analysts) rates it none, with a mean price target of $24. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-26Markdown$10.99+0.0%Entry 11
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it D. Technically it is momentum reading oversold. Over the past year the shares are up 2%. Our forward projection puts the odds of a 10% gain over the next month near 46%. The street (5 analysts) rates it none, with a mean price target of $24.
2026-10-19Markdown$10.99-19.5%Entry 10
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 19.5% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it D. Technically it is holding around 30% above its long-term trend line with momentum reading oversold. Over the past year the shares are up 2%. Our forward projection puts the odds of a 10% gain over the next month near 46%. The street (5 analysts) rates it none, with a mean price target of $24.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
